#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.MedicalEntity|DCT|MedicalEntity


#Text=05.04.2023:
#Text=Kvinne 68 år med progressive smerter i skulder- og hofteparti over 2 måneder.
1-1	0-10	05.04.2023	_	_	
1-2	10-11	:	_	_	
1-3	12-18	Kvinne	_	_	
1-4	19-21	68	_	_	
1-5	22-24	år	_	_	
1-6	25-28	med	_	_	
1-7	29-40	progressive	BEFOREOVERLAP[1]	CONDITION[1]	
1-8	41-48	smerter	BEFOREOVERLAP[1]	CONDITION[1]	
1-9	49-50	i	BEFOREOVERLAP[1]	CONDITION[1]	
1-10	51-58	skulder	BEFOREOVERLAP[1]	CONDITION[1]	
1-11	58-59	-	BEFOREOVERLAP[1]	CONDITION[1]	
1-12	60-62	og	BEFOREOVERLAP[1]	CONDITION[1]	
1-13	63-73	hofteparti	BEFOREOVERLAP[1]	CONDITION[1]	
1-14	74-78	over	_	_	
1-15	79-80	2	_	_	
1-16	81-88	måneder	_	_	
1-17	88-89	.	_	_	

#Text=Utpreget morgenstivhet >1 time.
2-1	90-98	Utpreget	_	_	
2-2	99-112	morgenstivhet	OVERLAP	CONDITION	
2-3	113-114	>	_	_	
2-4	114-115	1	_	_	
2-5	116-120	time	_	_	
2-6	120-121	.	_	_	

#Text=SR 68, CRP 55.
3-1	122-124	SR	OVERLAP	CONDITION	
3-2	125-127	68	_	_	
3-3	127-128	,	_	_	
3-4	129-132	CRP	OVERLAP	CONDITION	
3-5	133-135	55	_	_	
3-6	135-136	.	_	_	

#Text=Klinisk undersøkelse typisk for polymyalgia rheumatica.
4-1	137-144	Klinisk	OVERLAP[2]	CONDITION[2]	
4-2	145-157	undersøkelse	OVERLAP[2]	CONDITION[2]	
4-3	158-164	typisk	OVERLAP[2]	CONDITION[2]	
4-4	165-168	for	OVERLAP[2]	CONDITION[2]	
4-5	169-180	polymyalgia	OVERLAP[2]	CONDITION[2]	
4-6	181-191	rheumatica	OVERLAP[2]	CONDITION[2]	
4-7	191-192	.	_	_	

#Text=Starter Prednisolon 20mg daglig.
5-1	193-200	Starter	_	_	
5-2	201-212	Prednisolon	AFTER[3]	TREATMENT[3]	
5-3	213-217	20mg	AFTER[3]	TREATMENT[3]	
5-4	218-224	daglig	_	_	
5-5	224-225	.	_	_	

#Text=Henviser revmatolog.
6-1	226-234	Henviser	AFTER[4]	TREATMENT[4]	
6-2	235-245	revmatolog	AFTER[4]	TREATMENT[4]	
6-3	245-246	.	_	_	

#Text=Calcium/D-vitamin profylakse.
7-1	247-254	Calcium	AFTER[5]	TREATMENT[5]	
7-2	254-255	/	AFTER[5]	TREATMENT[5]	
7-3	255-264	D-vitamin	AFTER[5]	TREATMENT[5]	
7-4	265-275	profylakse	AFTER[5]	TREATMENT[5]	
7-5	275-276	.	_	_	
